Preterm labor: Current pharmacotherapy options for tocolysis

Elvira O.G. Van Vliet*, Elisabeth M. Boormans, Thomas S. De Lange, Ben W. Mol, Martijn A. Oudijk

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

25 Citations (Scopus)


Introduction: In the developed world, preterm birth is in quantity and in severity the most important issue in obstetric care. Adverse neonatal outcome is strongly related to gestational age at delivery. Since the pathophysiological mechanism of preterm birth is not yet completely unraveled, the development of successful preventive strategies is hampered. When preterm labor is actually threatening, current pharmacological therapies focus on inhibition of preterm contractions. This allows for transportation of the mother to a center with a neonatal intensive care unit and administration of corticosteroids to enhance fetal lung maturation. Globally, however, large practice variation exists. Areas covered: The aim of this review is to provide an overview of current pharmacological therapies for preterm labor. Expert opinion: For the initial tocolysis, the use of atosiban or nifedipine for 48 h is recommended based on the largest effectiveness and most favorable side effect profile. However, since data that convincingly indicate the beneficial effect of tocolytics on neonatal outcome are lacking, it might well be that tocolytics are ineffective. The role of progesterone in treatment of acute tocolysis is limited, but it might play a role in the prevention of preterm labor or as sensitizer for other tocolytic agents.

Original languageEnglish
Pages (from-to)787-797
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Issue number6
Publication statusPublished - Apr 2014


  • Pharmacotherapy
  • Preterm birth
  • Preterm labor
  • Tocolytics


Dive into the research topics of 'Preterm labor: Current pharmacotherapy options for tocolysis'. Together they form a unique fingerprint.

Cite this